- $1.47bn
- $1.58bn
- $418.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.12 | ||
| PEG Ratio (f) | 0.73 | ||
| EPS Growth (f) | 52.62% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.52 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 27 | ||
| Price to Sales | 3.61 | ||
| EV to EBITDA | 22.78 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.05% | ||
| Return on Equity | -1.89% | ||
| Operating Margin | -0.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 286.1 | 335.64 | 354.34 | 385.15 | 418.84 | 379.4 | 388.37 | 11.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +16.13 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Certara, Inc. is a provider of biosimulation science, technology, and consulting services for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical and biotech industry. The Company's proprietary biosimulation platforms are built on biology, chemistry, and pharmacology principles with proprietary mathematical algorithms that model how medicines and diseases behave in the body. It has developed scientifically-based solutions for the collection, standardization, validation, storage, and analysis of the preclinical, clinical and evidence data needed for MIDD. These data solutions are used internally and industry-wide by life sciences companies. The Company applies AI capabilities within established modeling environments and under the supervision of experienced scientists and regulatory experts. Its modeling platforms and curated datasets position it to incorporate emerging AI techniques in a controlled and scientifically rigorous manner.
Directors
- Sherilyn McCoy NEC (62)
- William Feehery CEO (51)
- M. Andrew Schemick CFO (47)
- Robert Aspbury CEX (49)
- Justin Edge CEX (52)
- Leif Pedersen CEX (56)
- Patrick Smith CEX
- Judith Dickinson CHO (47)
- Richard Traynor SVP (49)
- Jieun Choe CMO (46)
- Cynthia Collins DRC (63)
- Nancy Killefer DRC
- James Cashman IND (67)
- Carol Gallagher IND (56)
- Eric Liu IND (44)
- Stephen McLean IND (63)
- Mason Slaine IND (68)
- Matthew Walsh IND (54)
- Ethan Waxman IND (32)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 27th, 2017
- Public Since
- December 11th, 2020
- No. of Shareholders
- 23
- No. of Employees
- 1,515
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 152,538,780
- Address
- 4 Radnor Corporate Center, Suite 350, RADNOR, 19087
- Web
- https://www.certara.com/
- Phone
- +1 4152378272
- Auditors
- RSM US LLP
Latest News for CERT
Upcoming Events for CERT
Q3 2026 Certara Inc Earnings Release
Q4 2026 Certara Inc Earnings Release
Similar to CERT
Adobe
NASDAQ Global Select Market
Agilysys
NASDAQ Global Select Market
Agora
NASDAQ Global Select Market
Airbnb
NASDAQ Global Select Market
Akamai Technologies
NASDAQ Global Select Market
FAQ
As of Today at 01:53 UTC, shares in Certara are trading at $9.66. This share price information is delayed by 15 minutes.
Shares in Certara last closed at $9.66 and the price had moved by -19.3% over the past 365 days. In terms of relative price strength the Certara share price has underperformed the S&P500 Index by -30.92% over the past year.
The overall consensus recommendation for Certara is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCertara does not currently pay a dividend.
Certara does not currently pay a dividend.
Certara does not currently pay a dividend.
To buy shares in Certara you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $9.66, shares in Certara had a market capitalisation of $1.47bn.
Here are the trading details for Certara:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CERT
Based on an overall assessment of its quality, value and momentum Certara is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Certara is $8.80. That is 8.9% below the last closing price of $9.66.
Analysts covering Certara currently have a consensus Earnings Per Share (EPS) forecast of $0.34 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Certara. Over the past six months, its share price has outperformed the S&P500 Index by +42.57%.
As of the last closing price of $9.66, shares in Certara were trading +34.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Certara PE ratio based on its reported earnings over the past 12 months is 25.12. The shares last closed at $9.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Certara's management team is headed by:
- Sherilyn McCoy - NEC
- William Feehery - CEO
- M. Andrew Schemick - CFO
- Robert Aspbury - CEX
- Justin Edge - CEX
- Leif Pedersen - CEX
- Patrick Smith - CEX
- Judith Dickinson - CHO
- Richard Traynor - SVP
- Jieun Choe - CMO
- Cynthia Collins - DRC
- Nancy Killefer - DRC
- James Cashman - IND
- Carol Gallagher - IND
- Eric Liu - IND
- Stephen McLean - IND
- Mason Slaine - IND
- Matthew Walsh - IND
- Ethan Waxman - IND